Shionogi Inc - Strategic SWOT Analysis Review
Description
Shionogi Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services.
This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.
Scope
Shionogi Inc (Shionogi), a subsidiary of Shionogi & Co Ltd, is a pharmaceutical company that develops and commercializes pharmaceutical products to address unmet medical needs. The company offers a wide range of branded prescription products to treat chronic diseases. It markets products for various therapeutic areas such as pain, anti-infectives, women's health, pediatrics, cardiovascular, and others. Shionogi offers its products in various formulations such as tablets, oral suspensions (solutions), lotions, chewable tablets, capsules, and injections. Some of the company’s key branded products include Fortamet, and Methylin, among others. Shionogi is headquartered in Florham Park, New Jersey, the US.
Shionogi Inc Key Recent Developments
Feb 10,2026: Cumulus Neuroscience Enters Japanese Market to Advance Cognitive Biomarkers With Shionogi & Co., Ltd.
Dec 22,2025: Shionogi Expands Rare Disease Presence With Planned Acquisition of Global Rights to Tanabe Pharma Corporation’s RADICAVA ORS and IV RADICAVA
Dec 04,2025: Raya Therapeutic Announces Raya CARES Pipeline of Five Clinical-Stage Compounds
Dec 02,2025: Shionogi Inc. Appoints Ann Howell as Senior Vice President and Global Head of Regulatory Affairs
Reasons to Buy
This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.
Scope
- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – GlobalData’s summarization of the company’s business strategy.
- SWOT analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list of key locations and subsidiaries of the company, including contact details.
Shionogi Inc (Shionogi), a subsidiary of Shionogi & Co Ltd, is a pharmaceutical company that develops and commercializes pharmaceutical products to address unmet medical needs. The company offers a wide range of branded prescription products to treat chronic diseases. It markets products for various therapeutic areas such as pain, anti-infectives, women's health, pediatrics, cardiovascular, and others. Shionogi offers its products in various formulations such as tablets, oral suspensions (solutions), lotions, chewable tablets, capsules, and injections. Some of the company’s key branded products include Fortamet, and Methylin, among others. Shionogi is headquartered in Florham Park, New Jersey, the US.
Shionogi Inc Key Recent Developments
Feb 10,2026: Cumulus Neuroscience Enters Japanese Market to Advance Cognitive Biomarkers With Shionogi & Co., Ltd.
Dec 22,2025: Shionogi Expands Rare Disease Presence With Planned Acquisition of Global Rights to Tanabe Pharma Corporation’s RADICAVA ORS and IV RADICAVA
Dec 04,2025: Raya Therapeutic Announces Raya CARES Pipeline of Five Clinical-Stage Compounds
Dec 02,2025: Shionogi Inc. Appoints Ann Howell as Senior Vice President and Global Head of Regulatory Affairs
Reasons to Buy
- Gain key insights into the company for academic or business research purposes. Key elements such as SWOT analysis and corporate strategy are incorporated in the profile to assist your academic or business research needs.
- Identify potential customers and suppliers with this report’s analysis of the company’s business structure, operations, major products and services and business strategy.
- Understand and respond to your competitors’ business structure and strategies with GlobalData’s detailed SWOT analysis. In this, the company’s core strengths, weaknesses, opportunities and threats are analyzed, providing you with an up to date objective view of the company.
- Examine potential investment and acquisition targets with this report’s detailed insight into the company’s strategic, business and operational performance.
Table of Contents
40 Pages
- Section 1 - About the Company
- Shionogi Inc - Key Facts
- Shionogi Inc - Key Employees
- Shionogi Inc - Key Employee Biographies
- Shionogi Inc - Major Products and Services
- Shionogi Inc - History
- Shionogi Inc - Company Statement
- Shionogi Inc - Locations And Subsidiaries
- Head Office
- Other Locations & Subsidiaries
- Section 2 – Company Analysis
- Company Overview
- Shionogi Inc - Business Description
- R&D Overview
- Shionogi Inc - SWOT Analysis
- SWOT Analysis - Overview
- Shionogi Inc - Strengths
- Shionogi Inc - Weaknesses
- Shionogi Inc - Opportunities
- Shionogi Inc - Threats
- Shionogi Inc - Key Competitors
- Section 3 – Company’s Lifesciences Financial Deals and Alliances
- Shionogi Inc, Pharmaceuticals & Healthcare, Deals By Year, 2020 to YTD 2026
- Shionogi Inc, Pharmaceuticals & Healthcare, Deals By Type, 2020 to YTD 2026
- Shionogi Inc, Recent Deals Summary
- Section 4 – Company’s Recent Developments
- Feb 10, 2026: Cumulus Neuroscience Enters Japanese Market to Advance Cognitive Biomarkers With Shionogi & Co., Ltd.
- Dec 22, 2025: Shionogi Expands Rare Disease Presence With Planned Acquisition of Global Rights to Tanabe Pharma Corporation’s RADICAVA ORS and IV RADICAVA
- Dec 04, 2025: Raya Therapeutic Announces Raya CARES Pipeline of Five Clinical-Stage Compounds
- Dec 02, 2025: Shionogi Inc. Appoints Ann Howell as Senior Vice President and Global Head of Regulatory Affairs
- Nov 12, 2025: Shionogi Launches New Granules Formulation for Influenza Treatment
- Nov 05, 2025: New Clinical Data on Antiviral Treatments for Post-COVID-19 Condition
- Nov 04, 2025: Shionogi Pharma’s Kanegasaki Plant Receives BSI Kitemark Certification for Antimicrobial Manufacturing
- Oct 20, 2025: Global Fund Applauds GSK and ViiV Healthcare's £6 Million Commitment to Community Health Solutions
- Oct 15, 2025: Gareth Morgan Appointed President of Qpex Biopharma, Inc.
- Jul 08, 2025: ViiV Healthcare presents new data demonstrating positive real-world impact of its innovative long-acting injectables for HIV at IAS 2025
- Section 5 – Appendix
- Methodology
- About GlobalData
- Contact Us
- Disclaimer
- List of Tables
- Shionogi Inc, Key Facts
- Shionogi Inc, Key Employees
- Shionogi Inc, Key Employee Biographies
- Shionogi Inc, Major Products and Services
- Shionogi Inc, History
- Shionogi Inc, Subsidiaries
- Shionogi Inc, Key Competitors
- Shionogi Inc, Pharmaceuticals & Healthcare, Deals By Year, 2020 to YTD 2026
- Shionogi Inc, Pharmaceuticals & Healthcare, Deals By Type, 2020 to YTD 2026
- Shionogi Inc, Recent Deals Summary
- List of Figures
- Shionogi Inc, Pharmaceuticals & Healthcare, Deals By Year, 2020 to YTD 2026
- Shionogi Inc, Pharmaceuticals & Healthcare, Deals by Type, 2020 to YTD 2026
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
